Progesterone — the most misunderstood hormone

The premise

Progesterone is the hormone the prescriber gets wrong most often. Mainstream training treats "progesterone" and "progestin" as interchangeable terms, and the WHI breast-cancer headline contaminated a generation of providers against any agent in the class. The Nimbus position is precise: bioidentical progesterone (P4) is not equivalent to a synthetic progestin. The molecules have different receptor profiles, different downstream signaling, and different breast-cancer signal in human cohort data — the E3N (EPIC) cohort reported a relative risk of 1.00 for estradiol with bioidentical progesterone versus 1.16–1.69 for estradiol with synthetic progestins.^[E3N-2008] Oral progesterone is also metabolized to allopregnanolone — a GABA-A receptor positive allosteric modulator — which is the mechanism for its sleep, anxiolytic, and antidepressant effects.^{[allopregnanolone-GABA-A]} Synthetic progestins do not produce this metabolite.

This module trains the prescriber to pick the right molecule, the right formulation, the right dose, and to recognize the rare cases where intolerance is real and a Mirena IUD is the right answer.

Pre-test

Progesterone vs. progestins — the receptor and metabolite argument

A progestin is a synthetic analog with affinity for the progesterone receptor plus off-target activity at androgen, glucocorticoid, or mineralocorticoid receptors — depending on the specific molecule. The progestins encountered in primary care (medroxyprogesterone acetate, levonorgestrel, norethindrone, drospirenone, etonogestrel, dydrogesterone) each have a distinct off-target profile, and none of them are metabolized to allopregnanolone. Bioidentical progesterone is the molecule the corpus luteum produces — pregn-4-ene-3,20-dione — and after oral dosing it is metabolized in the liver and intestinal wall by 5α- and 5β-reductase to 5α- and 5β-pregnanolone (allopregnanolone), which act as positive allosteric modulators at the GABA-A receptor.^{[allopregnanolone-GABA-A]}

The same neurosteroid, given intravenously as brexanolone, is FDA-approved for severe postpartum depression — the human evidence that this pathway is clinically meaningful is now first-line for that indication.^{[brexanolone-PPD]}

The endometrial-protection literature for bioidentical progesterone anchors on the PEPI trial, which showed that micronized progesterone 200 mg given for 12 days per cycle alongside conjugated estrogens maintained endometrial safety comparable to medroxyprogesterone acetate while avoiding the lipid penalty MPA imposed.^[PEPI-1996] The Nimbus daily dosing rule extends that protection across all days of the month, which we cover below.

Daily, not cyclic — the Nimbus default for postmenopausal HRT

Mainstream gynecology often cycles a progestogen with estradiol to mimic the natural premenopausal cycle — for example, oral progesterone 200 mg nightly for the first twelve calendar days of each month. The Nimbus protocol is different: in postmenopausal HRT we dose progesterone daily and continuously.

The reasoning is mechanism-driven. The protective effects of progesterone — on endometrium, breast tissue, sleep architecture, central GABA tone, and bone — only apply on days the patient is actually taking it. A cyclic schedule leaves more than half the month uncovered. It also reintroduces predictable withdrawal bleeding, which is a quality-of-life cost the patient does not need to pay in the postmenopausal setting. Daily dosing is also easier for patients to comply with than a calendar-driven schedule.

TODO(citation): Identify a peer-reviewed head-to-head of cyclic vs. continuous progesterone for postmenopausal endometrial safety beyond PEPI. The Nimbus position is currently anchored in PEPI plus internal clinical experience; pending direct evidence, cite this as Nimbus policy.^{[nimbus-policy-02-progesterone-daily]}

Route selection — and why cream and pellet fail for endometrial protection

Five routes are clinically available for progesterone: oral, sublingual, vaginal, intramuscular, and topical (cream, pellet). They are not interchangeable.

• Oral micronized — capsule, typically 100–300 mg QHS. First-pass metabolism through liver and intestinal wall generates allopregnanolone, which produces the sleep and anxiolytic benefit. This is the Nimbus default for postmenopausal endometrial protection.
• Sublingual (SL) — rapid-dissolve tablet, troche, or triturate, up to 200 mg per dose. Bypasses first pass somewhat but the swallowed fraction still generates allopregnanolone, so mood and sleep benefits are preserved. Good for daytime dosing and for endometrial-stripe escalation as an adjunct to bedtime oral.
• Vaginal — insert, suppository, troche, or gel. Produces higher-than-predicted uterine tissue concentrations via the direct vaginal-to-uterine first-pass effect. However, vaginal mucosa lacks the 5α- and 5β-reductase activity needed to generate allopregnanolone — so vaginal progesterone provides endometrial protection but no mood or sleep benefit. Use when oral and SL are contraindicated or not tolerated.
• Intramuscular (IM) — progesterone in sesame oil, 50 mg/mL vial, dosed 100 mg IM stat (one 1 mL injection per buttock) for postpartum-depression emergency or pregnancy support per OB protocol. Deep IM is hard to self-administer.
• Topical cream and pellet — these do not achieve protective serum levels for endometrial coverage and the cream-pharmacy assay levels do not predict tissue protection. Pellets cannot be dose-adjusted once inserted and do not generate the neuroactive metabolites in clinically useful amounts. Both routes are excluded from the Nimbus endometrial-protection ladder.

The 3.5 conversion — LabCorp/Access to Quest

Postmenopausal progesterone targets differ between vendors because the assay platforms report on different scales. Multiply a LabCorp or Access result by 3.5 to compare it to the Quest scale.

Endometrial-stripe escalation

Any postmenopausal patient on estradiol who develops new bleeding or spotting needs a transvaginal ultrasound (TVUS) to measure the endometrial stripe.

• ≤ 5 mm — normal. Investigate other bleeding sources; reassess symptoms.
• 6–8 mm — high-dose progesterone: 200 mg SL RDT BID–QID plus immediate-release oral capsule 200–300 mg QHS until bleeding is controlled and the stripe normalizes on repeat TVUS.
• > 8 mm — refer to OB/GYN for endometrial biopsy. Do not attempt to manage from the HRT clinic alone.

The transvaginal probe is the standard imaging route; abdominal ultrasound under-resolves the endometrium and is not adequate.

TODO(citation): Cite a peer-reviewed source for the specific 5/6/8 mm cutoffs at Nimbus. ACOG and SGO use related cutoffs in the postmenopausal-bleeding workup; reconcile and add the published threshold.^{[nimbus-policy-02-progesterone-stripe]}

Mid-module checkpoint

Postpartum depression — the Nimbus emergency protocol

At placental delivery, maternal progesterone drops abruptly from luteal-of-pregnancy levels to near-zero. The allopregnanolone withdrawal that follows is a recognized trigger for postpartum mood disorders; brexanolone — synthetic allopregnanolone — is FDA-approved for severe postpartum depression on the strength of two phase-3 trials.^{[brexanolone-PPD]}

For an acute presentation at Nimbus the emergency dose is one of:

• Progesterone 100 mg IM stat — one 1 mL injection per buttock, drawn from a progesterone 50 mg/mL sesame-oil vial.
• Compounded sublingual RDT — 4 × 200 mg for a total of 800 mg SL, if IM is not geographically accessible.

Then transition to the 5-week compounded sublingual taper:

Co-manage with the patient's OB and a behavioral-health clinician for the duration of the taper, screen for suicidality at each encounter, and reassess at week 6 with formal PPD screening (EPDS) and a return-to-baseline check.

Heavy menstrual bleeding — up to 200 mg QID

For perimenopausal heavy menstrual bleeding or dysfunctional uterine bleeding, the Nimbus dose ladder uses high-dose sublingual progesterone 200 mg SL RDT BID, TID, or QID until bleeding stops, combined with an oral immediate-release capsule 200 mg or 300 mg QHS. Order a TVUS for endometrial-stripe assessment any time there is dysfunctional uterine bleeding so the escalation pathway above can be invoked when indicated.

TODO(citation): Cite a peer-reviewed protocol for high-dose oral or sublingual bioidentical progesterone in perimenopausal HMB. ACOG addresses progestogen for HMB but not specifically the 200 mg QID dose; reconcile.^{[nimbus-policy-02-progesterone-hmb]}

True progesterone intolerance — and the Mirena IUD fallback

True progesterone intolerance is rare — on the order of 1 in 1,000 women — and presents as extreme dysphoria, hives, rash, itching, and profound malaise that recurs across multiple routes. The first step in a suspected case is to switch formulation (oral to sublingual, sublingual to vaginal) and re-titrate, because drowsiness and dizziness are common dose-related side effects that respond to dose adjustment and are not the same as intolerance.

If symptoms reproduce across formulations, the patient has confirmed P4 intolerance and the Nimbus fallback is a Mirena IUD for endometrial protection while continuing systemic estradiol. The levonorgestrel-IUD delivers a progestin locally to the endometrium at a dose low enough that systemic exposure is minimal — endometrial protection is preserved without the dysphoria.

Progesterone in men — absolute contraindication

Do not prescribe progesterone to a patient born male. The reported effects include depression, suppressed libido, erectile dysfunction, fatigue and lethargy, disrupted T/DHT balance, increased visceral fat, and chronic inflammation — historically progesterone was used as "saltpeter" to reduce libido in incarcerated populations. This contraindication is absolute at Nimbus and is enforced at the prescribing layer.

Nimbus-vs-mainstream

Role-specific guidance

Key facts to memorize

Post-test

Module evaluation